Join DDW Editor Reece Armstrong and an expert line-up at the DDW Turning Science into Business Symposium at the Francis Crick Institute in London on Tuesday 4 November.

This free half-day event will feature six in-depth presentations from industry experts, a panel discussion examining new processes and technology, with a focus on how they can create efficiencies and expedite the drug discovery process, and an opportunity for networking.

Emma Mead
Professor Emma Mead

DDW is delighted to welcome Professor Emma Mead, Chief Scientific Officer of the Alzheimer’s Research UK Oxford Drug Discovery Institute, to the expert speaker line-up.

Mead will be presenting Innovations in target identification, validation and drug discovery for neurodegenerative diseases.

Emma Mead is Chief Scientific Officer, Alzheimer’s Research UK Oxford Drug Discovery Institute. She received her PhD in Neuroscience from University College London, investigating the role of reactive oxygen species in modulating neuroinflammation in Alzheimer’s disease. Following a post-doctoral research position at Cardiff University, Mead joined Eli Lilly working in target validation and early drug discovery for neurodegeneration. Emma joined the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) in 2018 to lead the Neuroinflammation team, and became the CSO in 2023.

The Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) is one of three institutes forming the Alzheimer’s Research UK Drug Discovery Alliance (DDA). Alongside the UCL Drug Discovery Institute and ALBORADA Drug Discovery Institute at the University of Cambridge, our goal is to couple the deep disease knowledge and biology expertise of the academic community with high quality, innovative drug discovery technologies. We aim to translate cutting edge academic science into drug discovery programmes and develop therapies for patients living with Alzheimer’s disease and other neurodegenerative conditions.

Mead will be joined by participants from Cancer Research Horizons-AstraZeneca Functional Genomics Centre, Oxford University, Apollo Therapeutics, University of Cambridge, Gain Therapeutics and Shift Bioscience.

Sponsors:

  • Nuclera (lead sponsor)
  • Collaborative Drug Discovery (coffee break sponsor)
  • Thermo Fisher Scientific (sponsor)

Registration is now open and is subject to availability and eligibility. Secure your place!